StockNews.AI
MDWD
StockNews.AI
169 days

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

1. MediWound will release Q4 2024 financial results on March 19, 2025. 2. A conference call will follow to discuss the financial performance. 3. MediWound focuses on next-gen enzymatic therapeutics for tissue repair. 4. NexoBrid® is FDA-approved; EscharEx® is in Phase III development. 5. EscharEx® may outperform a $375M competitor in wound debridement.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could reflect growth in sales, especially with EscharEx®.

How important is it?

The article discusses key developments and upcoming financial results that can influence the stock price.

Why Short Term?

The immediate release of Q4 results will influence investor sentiment shortly thereafter.

Related Companies

Milo(R)CRMDAVCO
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time March 03, 2025 08:00 ET  | Source: MediWound Ltd. YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:  1-833-630-1956Israel: 1-80-921-2373International: 1-412-317-1837Webcast: Click HERE    To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries. MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available $375+ million drug for wound debridement, presenting a unique opportunity for significant market growth. For more information visit www.mediwound.com and follow us on LinkedIn. MediWound Contacts: Hani Luxenburg Daniel FerryChief Financial Officer Managing DirectorMediWound Ltd. LifeSci Advisors, LLCir@mediwound.com daniel@lifesciadvisors.com   Media Contact: Ellie Hanson  FINN Partners for MediWound  ellie.hanson@finnpartners.com  +1-929-588-2008  

Related News